Maintenance Strategy in Ovarian Cancer

A major unmet need in ovarian cancer lies in extending disease control after initial treatment, especially for patients with homologous recombination proficient tumors who often derive less benefit from existing maintenance strategies. The discussion explores whether antibody drug conjugates might eventually play a role in this space if they can provide meaningful activity without creating unacceptable cumulative toxicity. Maintenance therapy raises a different standard than later line treatment because patients may remain on therapy longer, and long term tolerability becomes as important as antitumor effect. Sequencing is another major theme, particularly whether patients can benefit from one antibody drug conjugate after exposure to another that uses a different target but a similar payload. The faculty do not present maintenance use as established practice, but they identify it as an area of clear research interest. Better data on duration of benefit, quality of life, and optimal patient selection will be necessary before these therapies can be confidently moved into a broader maintenance strategy in ovarian cancer.